WallStSmart

Danaher Corporation (DHR)vsMedpace Holdings Inc (MEDP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Danaher Corporation generates 802% more annual revenue ($25.11B vs $2.78B). MEDP leads profitability with a 17.7% profit margin vs 16.0%. DHR appears more attractively valued with a PEG of 1.23. MEDP earns a higher WallStSmart Score of 68/100 (B-).

DHR

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 4/9Altman Z: 2.36

MEDP

Strong Buy

68

out of 100

Grade: B-

Growth: 9.3Profit: 9.0Value: 2.7Quality: 6.0
Piotroski: 4/9Altman Z: 1.83
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHRSignificantly Overvalued (-68.9%)

Margin of Safety

-68.9%

Fair Value

$118.49

Current Price

$203.23

$84.74 premium

UndervaluedFair: $118.49Overvalued
MEDPSignificantly Overvalued (-39.2%)

Margin of Safety

-39.2%

Fair Value

$304.57

Current Price

$587.52

$282.95 premium

UndervaluedFair: $304.57Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DHR4 strengths · Avg: 8.8/10
EPS GrowthGrowth
59.7%10/10

Earnings expanding 59.7% YoY

Market CapQuality
$140.97B9/10

Large-cap with strong market position

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.26B8/10

Generating 1.3B in free cash flow

MEDP5 strengths · Avg: 8.6/10
Return on EquityProfitability
113.3%10/10

Every $100 of equity generates 113 in profit

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

Operating MarginProfitability
20.8%8/10

Strong operational efficiency at 20.8%

Revenue GrowthGrowth
17.2%8/10

17.2% revenue growth

EPS GrowthGrowth
37.1%8/10

Earnings expanding 37.1% YoY

Areas to Watch

DHR2 concerns · Avg: 3.5/10
P/E RatioValuation
36.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

MEDP4 concerns · Avg: 3.0/10
P/E RatioValuation
34.7x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.834/10

Grey zone — moderate risk

PEG RatioValuation
2.812/10

Expensive relative to growth rate

Price/BookValuation
37.8x2/10

Trading at 37.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : DHR

The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 19.8%. PEG of 1.23 suggests the stock is reasonably priced for its growth.

Bull Case : MEDP

The strongest argument for MEDP centers on Return on Equity, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 20.8%. Revenue growth of 17.2% demonstrates continued momentum.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Return on Equity.

Bear Case : MEDP

The primary concerns for MEDP are P/E Ratio, Altman Z-Score, PEG Ratio.

Key Dynamics to Monitor

DHR profiles as a mature stock while MEDP is a growth play — different risk/reward profiles.

MEDP carries more volatility with a beta of 1.15 — expect wider price swings.

MEDP is growing revenue faster at 17.2% — sustainability is the question.

DHR generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MEDP scores higher overall (68/100 vs 66/100), backed by strong 17.7% margins and 17.2% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Medpace Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.

Want to dig deeper into these stocks?